EGFR and lung cancer: In conclusion, using in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to EGFR TKIs, metformin was found to inhibit proliferation and promote apoptosis of EGFR-mutant lung cancer cells, especially acquired resistant cells.